Literature DB >> 30143999

KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.

Takuyo Kanayama1, Toshihiko Imamura2, Yasuhiro Kawabe2, Shinya Osone2, Junko Tahara3, Fuminori Iwasaki4, Naoyuki Miyagawa4, Hiroaki Goto4, Shinsaku Imashuku3, Hajime Hosoi2.   

Abstract

Mixed lineage leukemia [MLL; now known as lysine methyltransferase 2A (KMT2A)] rearrangement-positive acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are distinct diseases, although age of susceptibility (infancy or early childhood) and abnormal monocytosis are common clinical features. Here, we report two cases of KMT2A-rearranged infantile AML masquerading as JMML at initial presentation. Both cases showed leukocytosis accompanied by atypical monocytosis. However, in both cases, leukemic blasts were absent at the initial examination. Thus, a diagnosis of JMML was suspected. However, initial cytogenetic analysis revealed that both cases had an 11q23 rearrangement, which is atypical in JMML. Eventually, due to the emergence of leukemic blasts and further cytogenetic studies, both cases were diagnosed with infantile AML with a KMT2A rearrangement. Although one patient remains in complete remission after the completion of AML appropriate chemotherapy, the other died of AML due to treatment failure. Our experience suggests that AML with KMT2A rearrangement should be considered for the differential diagnosis of infantile cases with atypical monocytosis suggestive of JMML. Cytogenetic studies, including fluorescence in situ hybridization analysis of KMT2A, may be helpful in distinguishing between AML with KMT2A rearrangement and JMML.

Entities:  

Keywords:  AML; Infantile; JMML; KMT2A; Monocytosis

Mesh:

Substances:

Year:  2018        PMID: 30143999     DOI: 10.1007/s12185-018-2522-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  8 in total

Review 1.  Juvenile myelomonocytic leukemia.

Authors:  M Aricò; A Biondi; C H Pui
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

Review 2.  How I treat juvenile myelomonocytic leukemia.

Authors:  Franco Locatelli; Charlotte M Niemeyer
Journal:  Blood       Date:  2015-01-06       Impact factor: 22.113

3.  Hematological malignancies with t(9;11)(p21-22;q23)--a laboratory and clinical study of 125 cases. European 11q23 Workshop participants.

Authors:  G J Swansbury; R Slater; B J Bain; A V Moorman; L M Secker-Walker
Journal:  Leukemia       Date:  1998-05       Impact factor: 11.528

4.  Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.

Authors:  Ichiro Tsukimoto; Akio Tawa; Keizo Horibe; Ken Tabuchi; Hisato Kigasawa; Masahiro Tsuchida; Hiromasa Yabe; Hideki Nakayama; Kazuko Kudo; Ryoji Kobayashi; Kazuko Hamamoto; Masue Imaizumi; Akira Morimoto; Shigeru Tsuchiya; Ryoji Hanada
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

Review 5.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

6.  New insights to the MLL recombinome of acute leukemias.

Authors:  C Meyer; E Kowarz; J Hofmann; A Renneville; J Zuna; J Trka; R Ben Abdelali; E Macintyre; E De Braekeleer; M De Braekeleer; E Delabesse; M P de Oliveira; H Cavé; E Clappier; J J M van Dongen; B V Balgobind; M M van den Heuvel-Eibrink; H B Beverloo; R Panzer-Grümayer; A Teigler-Schlegel; J Harbott; E Kjeldsen; S Schnittger; U Koehl; B Gruhn; O Heidenreich; L C Chan; S F Yip; M Krzywinski; C Eckert; A Möricke; M Schrappe; C N Alonso; B W Schäfer; J Krauter; D A Lee; U Zur Stadt; G Te Kronnie; R Sutton; S Izraeli; L Trakhtenbrot; L Lo Nigro; G Tsaur; L Fechina; T Szczepanski; S Strehl; D Ilencikova; M Molkentin; T Burmeister; T Dingermann; T Klingebiel; R Marschalek
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

7.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Authors:  D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

8.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.

Authors:  Brian V Balgobind; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Rob Pieters; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

  8 in total
  2 in total

Review 1.  Pediatric Neoplasms Presenting with Monocytosis.

Authors:  Jacob R Greenmyer; Mira Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

2.  MicroRNA-769-5p Promotes The Growth Of Glioma Cells By Targeting Lysine Methyltransferase 2A.

Authors:  Mingze Chang; Peng Yan; Bei Zhang; Gejuan Zhang; Juanhong Wang; Hanming Ge; Nannan Han; Chengxue Du; Wenzhen Shi; Ye Tian
Journal:  Onco Targets Ther       Date:  2019-11-05       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.